CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
- Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK
- Initiated Phase 1 study of cancer vaccine candidate, CVGBM, for surgically resected glioblastoma; recruitment of second dose cohort well on track
- Broadened position in patent litigations by expanding the scope and asserting new intellectual property rights in Germany and the U.S.
- Public hearing held before the Regional Court Düsseldorf as part of German patent litigation against Pfizer/BioNTech
- Cash and cash equivalents position of €537.9 million as of June 30, 2023
CureVac N.V. (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the second quarter and first half of 2023 and provided a business update.